The abstract is read at the publisher; the summary is JClub's.
In heart failure cohorts, low-dose mineralocorticoid receptor antagonists raise median aldosterone to 310 pg/mL yet incompletely block MR activity, with outcomes depending on baseline aldosterone.
- Why it matters: Guidelines recommend low-dose MRAs, but they can increase aldosterone, potentially leaving ongoing mineralocorticoid receptor stimulation. This analysis tests whether baseline and aldosterone changes during therapy track MR activity and clinical outcomes.
- What they did: Pooled patient-level analyses across DOSE, CARRESS-HF, MDR, and TOPCAT (n = 1019) related pre-MRA aldosterone and MRA use to MR activity, with urine sodium to potassium ratio quantifying MR activity in MDR (n = 136). Clinical outcomes were meta-analysed using these cohorts plus EARLIER (n = 300) and EPHESUS (n = 453).
- The result: MRA use was linked to higher aldosterone (310 vs 174 pg/mL, P < .001). In MDR, higher aldosterone correlated with higher MR activity, and MRA initiation reduced MR activity only in patients with high pre-MRA aldosterone, while it increased MR activity in those with low pre-MRA aldosterone; outcome associations also depended on baseline aldosterone (P interaction = .005).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.